NCT04792801Active, not recruiting
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
Evaluation of PET TDM FDG-Choline as a Decision-making Tool for Routine Care on Inclusion on the Liver Transplant List for Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PET CT scan is not currently recommended in the pre-liver transplant workup for HCC. However, PET CT using in a complementary manner the FDG and Choline tracers appears promising in the management of HCC in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. In order to address this issue, a prospective cohort study including patients from the University Hospital of Rouen and Lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in SPC will be set up, the main objective of which will be to assess the decision-making contribution of PET TDM FDG and Choline in addition to conventional imaging in the pre-transplant assessment.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 108 (actual)
- First submitted
- 8 Mar 2021
- Start date
- 22 Jun 2021
- Primary completion date
- 5 Jun 2028
- Lead sponsor
- University Hospital, Lille
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04792801
What you commit to
- Study type: Observational
- Participants enrolled: 108
- From 22 Jun 2021 to the primary completion date, 5 Jun 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Diabetes unbalanced HbA1c\> 9%, and fasting hyperglycemia (\> 2g / L) which does not allow the completion of the PET examination.
Other
- Patient with an AFP score ≥ 3
- Patient contraindicated to PET FDG or Choline.
- Other tumor: Cholangiocarcinoma.
- Patient under guardianship or curatorship.
- Pregnant or breastfeeding woman.
Who the study is looking for
- Patient candidate for liver transplantation for hepatocellular carcinoma from the University Hospital of Lille and Rouen, whose therapeutic transplantation project has been validated and having an AFP score ≤ 2 (diagnosis of HCC defined on non-invasive imaging criteria according to the recommendations of EASL-EORTC 2012 or confirmed histologically).
- No opposition to participating in the study.
- Patient affiliated to a social security scheme
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hop Claude Huriez Chu Lille Coordinator of this site? Confirm its status | Lille | France | Unknown status |
| CHU Rouen Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.